Allergic rhinitis is the most common atopic disorder affecting millions people annually all over the world. The choice of the optimal treatment of allergic rhinitis depends on different factors and conditions. The best option is avoidance of implicated allergens, but unfortunately it is not always possible and most of patients using symptomatic drugs. We compared 2 groups of patients with chronic allergic rhinitis. The first one was taking just Levocetirisinum 5 mg daily. And patients of the second group except Levocetirisinum 5 mg where taking Montelucastum 10 mg. Assessment of nasal symptoms was performed using TOTAL NASAL SYMPTOM SCORE at the beginning of the study, 10 and 30 days later. By the 10th day of treatment, there was a marked decrease in the severity of nasal symptoms in both groups. More significant reduction in the severity of nasal congestion was found among patients who received both Levocetirisinum and Montelucastum. Also the use of montelukastum as an additional drug in symptomatic therapy of chronic allergic rhinitis reduces the need for intranasal topical glucocorticosteroids compared to patients who received only antihistamines per os
